Kinnate Biopharma Inc. (KNTE)
Kinnate Biopharma Max Pain By Strike
KNTE trades at $2.65, 99.7% below the near-term max pain of $980 expiring Jan 16, 2026 (153 days). Look for upward drift as max pain acts as a magnet pulling price higher. Max pain is stable across expirations ($980-$980), indicating stable market expectations. High dispersion in max pain levels suggests competing forces and potential volatility.
Kinnate Biopharma Max Pain By Expiry
Max pain for KNTE shows stable levels around 980.00, reflecting balanced market expectations. The 0% spread suggests strong consensus on fair value. Most levels above 2.65 could support dips. Weekly expirations influence price 2-3 days before expiry; monthlies throughout their final week.
Max Pain Table
| Expiration Date | Max Pain | Max Pain vs Current Price |
|---|---|---|
| Jan 16, 2026 | 980 | 977.35 (36881.13%) |